Verteporfin sNDA approval expected by late April, QLT says, following submission of 24-month visual acuity data from Phase IIIb trial in pathologic myopia patients and Phase II data on ocular histoplasmosis syndrome. The submission responds to issues raised in Feb. 2 "approvable" letter from FDA. User fee date for the supplemental NDA pushed back to July 30, but QLT expects FDA action before then. Supplemental NDA, submitted Aug. 14, 2000, is for classic subfoveal choroidal neovascularization caused by pathologic myopia and ocular histoplasmosis syndrome
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth